A triple combination involving OpdualagTM, and the CTLA4 inhibitor Yervoy is being tried for treatment of advanced melanoma and initial results after 49.4-month median follow-up of a cohort in the phase 1/2 RELATIVITY-048 (NCT03459222) trial show confirmed ORR of 58.7% and a 48-month OS rate of 69.1%. This evidence concerns the gene CTLA4 and melanoma.